This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. When it comes to achieving a healthy body weight, some men might look to what’s average and use that as their goal. For instance, the ...
About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...
Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results